Efpeglenatide
No brand name yet
Hanmi's weekly GLP-1 agonist, once licensed to Sanofi for diabetes and returned in 2020. Approved in South Korea for weight management in October 2026 on a 448 person domestic phase 3.
Efpeglenatide comes from Hanmi Pharmaceutical and sits in the Incretins class on the board. Route: weekly injection. Use tracked here: Chronic weight management in adults without diabetes with obesity, or overweight with a weight related condition. It stands at Approved on the board, with 2 news moves logged; the latest is dated 2 Nov 2026.
- 05ApprovedHere now
- 04FiledApplication submitted to a regulator and under review.
- 03Phase 3Large confirmatory trials meant to support a filing.
- 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
- 01Phase 1First doses in people. Safety, dose range, how the body handles it.
- Company
- Hanmi Pharmaceutical
- Mechanism
- Long acting GLP-1 receptor agonist
- Given as
- weekly injection
- Lead use on the board
- Chronic weight management in adults without diabetes with obesity, or overweight with a weight related condition
- Moves logged
- 2latest 1 day ago
Efpeglenatide news moves
-
Efpeglenatide launch in Korea undercuts Mounjaro and Wegovy on price
Hanmi's weekly GLP-1 injection reached Korean hospitals on 29 October with a first month priced below Mounjaro and Wegovy. Trial weight loss trails the leaders, supply is limited, and insurance decisions could narrow the gap.
-
Efpeglenatide approval makes Hanmi the first Korean maker of a GLP 1 obesity drug
South Korea's regulator cleared Hanmi's weekly efpeglenatide injection for chronic weight management after a 448 person domestic phase 3. Weight loss trails the market leaders; Hanmi is betting on tolerability and local supply.
Other incretins molecules on the board, with their current stage.